I løbet af en randomiseret aftrapningsperiode fik signifikant flere patienter, som var gen- randomiseret til placebo, sygdomstilbagefald (tab af PASI 75 respons) sammenlignet med patienter, som var gen - randomiseret til Enbrel.
During a randomised withdrawal period, significantly more patients re-randomised to placebo experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to Enbrel.